FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number 3235-0104 Estimated average burden

			Filed	nursuant to S	ion 16(a) of the Securities Exchange Act of 1934			hours per res	sponse:	0.5	
				T lice	or Section 3	0(h) of the Investment Company Act of 1940					
(Month				22. Date of Event Requiring Statement (Month/Day/Year) 3. Issuer Name and Ticker or Trading Symbol <u>Health Catalyst, Inc.</u> [HCAT]							
(Last) (First) (Middle) C/O HEALTH CATALYST, INC. 3165 MILLROCK DRIVE, #400						4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below)	10% Owner Other (specify below) ficer		5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)		
(Street) SALT LAKE CITY UT 84121						Chief Operating Of			X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)									
				Table	I - Non-De	erivative Securities Beneficially Owned					
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership For (D) or Indirect (I)	m: Direct 4. Nat (Instr. 5)	Direct 4. Nature of Indirect Beneficial Ownership (Instr. 5) tr. 5)			
Common Stock					60,078	D					
						vative Securities Beneficially Owned warrants, options, convertible securitie	s)				
1. Title of Derivative Security (Instr. 4)				2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion o Exercise Price of Derivative	r 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	al
				Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security			
Stock Option (Right to Buy)				(1)	01/04/2022	Common Stock	50,000	2.46	D		
Stock Option (Right to Buy)			(2)	11/09/2025	Common Stock	202,500	10.3	D			

Stock Option (Right to Buy) Stock Option (Right to Buy)

Explanation of Responses:

This stock option award is fully vested and exercisable.
25% of the shares vested on October 28, 2016; and the remaining 75% vest in 36 equal monthly installments thereafter

2. 25% of use shares vestee on Cucuer 48, 2010; and the remaining /5% vest in 30 equal monthly installments thereafter.
3. The stock option vests based on the satisfaction of both a time-based vesting condition and a liquidity-based vesting condition. The time-based vesting condition is satisfied as follows: 25% of the shares subject to the stock option will satisfy the time-based vesting condition in 36 equal monthly installments thereafter, generally subject to the Reporting Person's continuous service relationship with the Company through each applicable vesting date. The liquidity-based vesting condition on A Epitember 25, 2019 and the eramining 75% will satisfy the time-based vesting condition in 36 equal monthly installments thereafter, generally subject to the Reporting Person's continuous service relationship with the Company through each applicable vesting date. The liquidity-based vesting condition on February 5, 2020 and the remaining 75% will satisfied as follows: 25% of the shares subject to the stock option will satisfy the time-based vesting condition is satisfied as follows: 25% of the shares subject to the stock option will satisfy the time-based vesting condition on February 5, 2020 and the remaining 75% will satisfied as follows: 25% of the shares subject to the stock option will satisfied use to the stock option of both a time-based vesting condition on February 5, 2020 and the remaining 75% will satisfied as a follows: 25% of the shares subject to the stock option will satisfied use to the stock option will satisfied use to the stock option will satisfied use to the company is initial public offering or a sale of the Company.

Common Stock

Common Stock

Remarks:

Exhibit 24 - Power of Attorney

<u>/s/ Daniel Orenstein, as Attorney-in-Fact</u> ** Signature of Reporting Person 07/24/2019 Date

10.8

15.84

D

D

500,000

300.000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(3)

(4)

09/27/2028

02/05/2029

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Daniel Orenstein, J. Patrick Nelli and Jason Alger, signing singly, the under (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Health Catalyst, Inc. (the "Company"), (i) Form 1

(2)

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Scht (3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the bes The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, (This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's H

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of July, 2019.

/s/ Dale Sanders

Name: Dale Sanders